Under construction – not a live service
Sign in
Taking people in ChinaNo phase

Immediate Angioplasty for Stroke From Severe Brain Artery Narrowing

Tests immediate angioplasty in adults with stroke caused by severe brain artery narrowing.

Key facts

Who runs it
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Where
Guangzhou and Shenzhen, ChinaSee the 2 sites
Trial code
Registry title
Immediate Angioplasty For Acute Ischemic Stroke With Severe Intracranial Atherosclerotic Stenosis
Status
Recruiting
People taking part
412 people, planned
Started
8 May 2025
Expected to end
Dec 2029
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Immediate angioplasty
Record updated
25 May 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with an acute ischemic stroke caused by a severely narrowed artery inside the brain. It tests immediate angioplasty, with or without a stent, on recovery at 90 days.

Age
18 years or older.
Sex
All sexes can join.
Disease stage
Acute ischemic stroke with NIHSS ≥6 and non-contrast CT ASPECTS score ≥6. Symptom onset (last known well) to randomization ≤ 24 hours. CTA shows severe narrowing (70-99%) of the intracranial internal carotid artery, or M1 or M2 segment of the middle cerebral artery, thought to cause the stroke.
Earlier treatment
Before the stroke, mRS must be ≤2. No other prior treatment is required.
Biomarker or test result
CTA-confirmed severe intracranial atherosclerotic stenosis (70-99%) of the culprit vessel.

Main reasons for not taking part

  • Bleeding in the brain on CT or MRI, or a hemorrhagic stroke in the past 90 days
  • Known heart source of clots, such as atrial fibrillation, patent foramen ovale or infective endocarditis
  • Pregnant or breastfeeding women
  • Severe kidney problems (glomerular filtration rate <30 ml/min or blood creatinine >220 μmol/L (2.49 mg/dL)), or severe allergy to contrast
  • Expected life expectancy <3 months, or taking part in another intervention trial

The registry criteria, word for word

Show all 27 criteriaShow less

Who can take part

  • Aged 18 years or older
  • Diagnosed with AIS and baseline NIHSS ≥6
  • Pre-stroke mRS ≤2
  • Time from symptom onset to randomization ≤ 24 hours; the onset time refers to "Last Known Well" (LKW)
  • Non-contrast CT ASPECTS score ≥6
  • CTA confirmed severe ICAS (70-99%) of the intracranial segment of the internal carotid artery, or M1 or M2 segment of the middle cerebral artery, and is presumed to be responsible for the stroke
  • Informed consent signed by the patient or authorized representative

Who cannot take part

  • Concomitant intracranial tumor (except for meningioma <10mm) or arteriovenous malformation
  • Hemorrhagic stroke within the past 90 days
  • Cerebrovascular conditions such as vasculitis, moya-moya disease, arterial inflammatory stenosis, vasospasm, traumatic dissection, etc
  • Known cardiac thrombus source (e.g., atrial fibrillation, patent foramen ovale, infective endocarditis)
  • Intracranial hemorrhage confirmed by CT or MRI
  • Severe allergy to contrast (non-mild rash allergy) or absolute contraindication to iodine contrast
  • Any active bleeding or recent bleeding in the last 1 month
  • Anticipated life expectancy <3 months (e.g., malignancy, severe cardiopulmonary disease, etc.)
  • Any condition that, in the judgment of the investigator, makes the patient unsuitable for this study or where this study may impose a significant risk to the patient (e.g., inability to understand and/or comply with study procedures and/or follow-up due to psychiatric disorders, cognitive or emotional impairment)
  • INR >1.7 when using warfarin; coagulation dysfunction or uncorrectable bleeding factors
  • Platelet count <50×10\^9/L
  • Known severe renal insufficiency with glomerular filtration rate <30 ml/min or blood creatinine >220 μmol/L (2.5 mg/dl)
  • Normal diameter of the culprit vessel <2.0 mm
  • Isolated perforator artery infarction (except for combined cortical hypoperfusion)
  • Severe calcification at the stenosis site, where expected residual stenosis ≤50% cannot be achieved with procedure
  • Women who are pregnant or breastfeeding
  • Participation in other intervention clinical trials
  • Aortic dissection
  • Severe vascular tortuosity, difficult access for intervention, or inability to complete endovascular treatment
  • SBP>185 mmHg or DBP>110 mmHg refractory to treatment

Where in China

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen UniversityGuangzhou, ChinaContact: Yang Xinguang, M.D.Taking people
  • Shenzhen Hospital of Southern Medical UniversityShenzhen, ChinaContact: Xiongjun He, M.D., Ph.D.Taking people

About the trial

What the trial wants to find out

A multicenter, prospective, open-label, blinded endpoint, randomized controlled trial that aims to evaluate the effect of immediate angioplasty (with or without stenting) for acute ischemic stroke (AIS) with severe intracranial atherosclerotic stenosis (ICAS) in improving the 90-day functional outcome.

The 2 groups in the trial

  • The intervention groupTreatment being tested

    Participants will receive immediate angioplasty (with or without stenting) for the culprit vessel and the target residual stenosis should be less than 50%. All participants will receive the best medical treatment (BMT).

    Treatment: Immediate angioplasty

  • The control groupNo study treatment, for comparison

    Participants will receive BMT alone.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Immediate Angioplasty For Acute Ischemic Stroke With Severe Intracranial Atherosclerotic Stenosis (MAGIC): A Multicenter, Prospective, Open-label, Blinded Endpoint, Randomized Controlled Trial
Plain-language title
Immediate Angioplasty for Stroke From Severe Brain Artery NarrowingGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
25 May 2025